William Blair Investment Management LLC purchased a new stake in Glaukos Co. (NYSE:GKOS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 809,589 shares of the medical instruments supplier's stock, valued at approximately $121,390,000. William Blair Investment Management LLC owned about 1.47% of Glaukos as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors also recently modified their holdings of the business. IFP Advisors Inc bought a new position in Glaukos in the fourth quarter valued at about $43,000. Asset Planning Inc bought a new stake in shares of Glaukos during the 4th quarter valued at approximately $90,000. Harvest Fund Management Co. Ltd increased its position in Glaukos by 2,263.2% during the 3rd quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier's stock worth $117,000 after purchasing an additional 860 shares in the last quarter. Picton Mahoney Asset Management acquired a new position in Glaukos during the 4th quarter worth approximately $125,000. Finally, SBI Securities Co. Ltd. bought a new position in Glaukos in the 4th quarter valued at approximately $153,000. Institutional investors and hedge funds own 99.04% of the company's stock.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on the stock. Mizuho upgraded shares of Glaukos from a "neutral" rating to an "outperform" rating and upped their price target for the stock from $140.00 to $200.00 in a report on Wednesday, February 19th. Piper Sandler reaffirmed an "overweight" rating and issued a $180.00 target price (up previously from $140.00) on shares of Glaukos in a report on Monday, January 27th. Stephens raised Glaukos to a "strong-buy" rating in a research note on Monday, December 2nd. Stifel Nicolaus upped their price objective on Glaukos from $153.00 to $175.00 and gave the company a "buy" rating in a research note on Tuesday, December 31st. Finally, UBS Group initiated coverage on shares of Glaukos in a report on Friday, December 6th. They issued a "buy" rating and a $182.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Glaukos has an average rating of "Moderate Buy" and an average target price of $163.25.
Read Our Latest Stock Report on Glaukos
Glaukos Trading Up 1.4 %
GKOS traded up $1.39 during trading on Friday, reaching $102.02. 1,040,792 shares of the stock traded hands, compared to its average volume of 585,959. The stock's 50-day moving average is $136.42 and its 200 day moving average is $136.75. Glaukos Co. has a 12 month low of $86.74 and a 12 month high of $163.71. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $5.77 billion, a PE ratio of -35.55 and a beta of 0.99.
Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The business had revenue of $105.50 million for the quarter, compared to analyst estimates of $100.72 million. Equities analysts anticipate that Glaukos Co. will post -1.08 earnings per share for the current year.
Insider Activity
In other news, insider Tomas Navratil sold 3,416 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now owns 72,437 shares of the company's stock, valued at $10,658,380.18. This represents a 4.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 6.40% of the stock is currently owned by company insiders.
Glaukos Company Profile
(
Free Report)
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Further Reading
Before you consider Glaukos, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.
While Glaukos currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
